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ABSTRACT
Androgens and the androgen receptor (AR) play crucial roles in male development 
and the pathogenesis and progression of prostate cancer (PCa). The AR functions 
as a ligand dependent transcription factor which recruits multiple enzymatically 
distinct epigenetic coregulators to facilitate transcriptional regulation in response 
to androgens. Over-expression of AR coregulators is implicated in cancer. We 
have shown that over-expression of KDM1A, an AR coregulator, contributes to PCa 
recurrence by promoting VEGFA expression. However the mechanism(s) whereby AR 
coregulators are increased in PCa remain poorly understood. In this study we show 
that the microRNA hsa-miR-137 (miR137) tumor suppressor regulates expression of 
an extended network of transcriptional coregulators including KDM1A/LSD1/AOF1, 
KDM2A/JHDM1A/FBXL11, KDM4A/JMJD2A, KDM5B JARID1B/PLU1, KDM7A/JHDM1D/
PHF8, MED1/TRAP220/DRIP205 and NCoA2/SRC2/TIF2. We show that expression of 
miR137 is increased by androgen in LnCaP androgen PCa responsive cells and that the 
miR137 locus is epigenetically silenced in androgen LnCaP:C4-2 and PC3 independent 
PCa cells. In addition, we found that restoration of miR137 expression down-regulates 
expression of VEGFA, an AR target gene, which suggests a role of miR137 loss also 
in cancer angiogenesis. Finally we show functional inhibition of miR137 function 
enhanced androgen induction of PSA/KLK3 expression. Our data indicate that miR137 
functions as an androgen regulated suppressor of androgen signaling by modulating 
expression of an extended network of transcriptional coregulators. Therefore, we 
propose that epigenetic silencing of miR137 is an important event in promoting 
androgen signaling during prostate carcinogenesis and progression.
INTRODUCTION
Epigenetic silencing of tumor suppressor 
microRNAs (miRs) has recently emerged as an important 
mechanism of carcinogenesis [1]. MiRs are endogenous 
mediators of RNA silencing which function to attenuate 
transcriptional and translational outputs [2]. Each miR can 
functionally interfere with multiple target mRNAs in vivo, 
and thus a single miR has the potential to down-regulate 
an extended network of transcriptional targets. Conversely, 
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the epigenetic loss of a specific miR would permit 
increased expression of multiple target genes. Numerous 
examples of such tumor suppressor miRs have been 
described [reviewed in 1, 3]. Epigenetic silencing of hsa-
miR-137 (miR137) has recently emerged as an important 
event in neuroblastoma [4], glioblastoma [5], colorectal 
[6, 7], breast [8], head and neck [9, 10] and bladder [11] 
cancers. Known, validated targets for miR137 include the 
cell cycle regulator Cdc42 [7], estrogen related receptor 
ERRα/NR3B1 [12], p160 nuclear receptor coactivators 
[13] and the lysine specific demethylase 1 (KDM1A, 
LSD1), a transcriptional coregulator [6] which is over-
expressed in many cancers [14 and references therein]. 
Loss of miR137 expression is associated with increased 
cell proliferation and invasion, consistent with a role in 
metastatic disease [6].
KDM1A plays important roles in androgen receptor 
(AR) signaling [15, 16] and is over-expressed in recurrent 
prostate cancer (PCa) [14, 17]. The AR is a member of 
the ligand dependent transcription factor superfamily of 
nuclear receptors and mediates the transcriptional actions 
of the androgens, testosterone, and dihydrotestosterone. 
The AR itself plays an essential role both in male 
development [18] and prostate [19] and other cancers 
[20]. Nuclear receptors, including the AR, recruit multiple 
enzymatically diverse transcriptional coregulators in 
response to agonist activation [21 and references therein]. 
These transcriptional coregulators are essential mediators 
of the epigenetic regulation of transcription by modulating 
histone modifications, including lysine methylation and 
acetylation [reviewed in 22, 23]. These coregulators 
mediate the transcriptional activities of other nuclear 
receptors, most notably the estrogen receptors [24] and 
other transcription factors [23]. Aberrant expression and 
function of transcriptional coregulators are implicated in 
numerous human malignancies, including PCa [14, 23, 
25-29]. 
We [14] and others [15-17] have reported that 
expression of KDM1A is increased in PCa and is 
associated with poorer outcomes. We have also shown 
that KDM1A contributes to poorer prostate outcomes by 
promoting pro-androgenic and pro-angiogenic pathways 
[14]. However understanding of the mechanism(s) 
contributing to increased expression of KDM1A and other 
coregulators [30] in PCa remains incomplete. In this report 
we first sought to determine whether specific microRNAs, 
including miR137, which are expressed in normal 
prostate cells but lost in PCa cells, function as repressors 
of KDM1A. Our analysis revealed that miR137 targets 
an extended network of transcriptional coregulators, 
including KDM1A/LSD1/AOF1, KDM2A/JHDM1A/
FBXL11, KDM4A/JMJD2A, KDM5B/JARID1B/PLU1, 
KDM7A/JHDM1D/PHF8, MED1/TRAP220/DRIP205 
and NCoA2/SRC2/TIF2. Ectopic restoration of miR137 
expression decreases expression of these transcriptional 
coregulators. We show that restoration of miR137 function 
is associated with a decrease in VEGFA expression which 
we have previously shown to be positively regulated by the 
AR-KDM1A complex [14]. We show that expression of 
miR137 is increased by androgen in androgen-responsive 
cells. Finally, we show that functional inhibition of 
miR137 enhances androgen signaling. Our data indicates 
that the epigenetic status of the miR137 locus influences 
expression of an extended network of transcriptional 
coregulators and that miR137 functions as an androgen 
regulated suppressor of epigenetic coregulators. We 
therefore propose that epigenetic silencing of miR137 is an 
important event in promoting androgen signaling during 
prostate carcinogenesis and progression.
RESULTS
Expression of miR137 is epigenetically silenced by 
DNA methylation in prostate cancer cells 
Expression of KDM1A is increased in many solid 
tumors and leukemias [14 and references therein]. 
However the mechanisms whereby KDM1A expression 
is increased remain poorly understood. One potential 
mechanism relates to the loss of a repressor microRNA 
[31]. We therefore used the PicTar [32], Targetscan 
[33], miRDB [34] and miRanda [35] microRNA target 
prediction tools and identified miR137 as a potential 
regulator of KDM1A (Figure 1A, Supplemental Table 1). 
MiR137 was also recently shown to regulate KDM1A in 
colon cancer [6] and neuroblastoma [4]. MicroRNAs are 
known to regulate expression of multiple targets which 
are often functionally related. For this reason we next 
examined whether miR137 also regulated expression 
of genes functionally related to KDM1A. Our analysis 
identified KDM2A, KDM4A, KDM5B, KDM7A, MED1, 
CBP, and SUZ12 as potential miR137 targets in PCa. 
By real time qPCR we detected abundant expression of 
miR137 in normal prostate epithelial cells (PREC), but 
reduced miR137 expression in LnCaP (representative 
of localized PCa) and absent miR137 expression in 
LnCaP:C4-2 (a bone metastatic derivative of the parental 
LnCaP cell line) and PC3 (representative of aggressive 
androgen independent metastatic PCa) (Figure 1B). We 
next used bisulfite sequencing PCR (BSP) to determine 
the DNA methylation status of miR137 locus in PREC 
and LNCaP. We confirmed these findings by completing 
methylation specific PCR (MSP) in PREC, LnCaP, 
LnCaP:C4-2 and PC3 cells. MSP and BSP indicate 
extensive methylation of the miR137 locus in PCa cell lines 
(Figure 1C, 1D). We next assessed the DNA methylation 
status of the miR137 locus in publically available patient 
genomic datasets [36] and the cancer genome atlas 
prostate adenocarcinoma (PRAD) DNA methylation 
dataset. The miR137 locus harbors significantly higher 
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Figure 1: A. Venn diagram of putative miR137 target genes identified by four different tools. B. Quantitative RTPCR was used to measure 
miR137 expression in prostate cells. Normal prostate epithelial cells (PREC) exhibited the most abundant miR137 expression as compared 
to LnCaP, LnCaP:C4-2 and PC3 PCa cells. C. Genomic DNA was isolated from prostate epithelial cells (PREC) and PCa cell lines, LNCaP, 
LNCaP:C4-2 and PC3 cells and subjected to bisulfite modification. The location of the miR137 transcript relative to the CpGs analyzed is 
indicated. Methylation specific PCR was used to assess methylation a crucial CpG island. The miR137 locus was unmethylated in normal 
PREC, but hemi-methylated in LNCaP and LNCaP:C4-2 cells. The miR137 locus in PC3 was methylated. D. BSP primers were used to 
amplify the entire CpG island of the miR137 locus in PREC and PC3 cells. The miR137 locus was unmethylated in normal PREC, but 
densely methylated in PC3 PCa cells. Black circles indicate methylated CpGs, whereas white circles indicate unmethylated CpGs. The data 
represent a minimum of 10 independent alleles from each respective cell line. Consistent with the literature, methylation of the miR137 
locus in PCa cells correlates with lower miR137 expression as compared with the unmethylated miR137 locus in normal PREC. E. We 
used the cancer genome atlas prostate adenocarcinoma (PRAD) dataset DNA methylation dataset to correlate methylation of the miR137 
locus and Gleason grade. Increased DNA methylation (indicated in yellow) at the cg05423529, cg14783814 and cg22333214 locations in 
the miR137 locus is significantly associated (t test with Benjamini-Hochberg FDR) with Gleason grades ≥8 patient sub-group (indicated in 
green, N-196) as compared to patients with Gleason grades ≤7 (indicated in red, n = 323). 
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methylation in tumor tissue as compared to non-malignant 
tissue in a variety of human cancer types, including PCa 
(Supplemental Figure 1). Indeed increased miR137 
methylation correlates with increasing PCa Gleason grade 
(Figure 1E). We have shown that expression of miR137 
was significantly lower in all PCa cells relative to normal 
prostate epithelial cells (Figure 1B). Consistent with this, 
our analysis of a published PCa patient transcriptomic 
cohort, shows that median miR137 expression is 
lower in PCa patients who experience PCa recurrence 
(Supplemental Figure 2A), indicating epigenetic loss of 
miR137 expression is associated with PCa recurrence [37]. 
An extended network of transcriptional 
coregulators are novel miR137 targets in vitro 
Novel putative miR137 targets were prioritized 
for experimental validation if they were identified by a 
minimum of two tools, had a transcription coregulator-
related function, and were expressed in PCa cells 
(Supplemental Table 1). To this end we examined mRNA 
expression of the putative miR137 targets identified here, 
KDM1A, KDM2A, KDM2A, KDM5B, KDM7A, CBP, 
SUZ12, MED1, and NCoA2 in normal and malignant 
PCa cells (Figure 2A-2I). Interestingly, the expression 
of all putative miR137 targets tested was similar or 
elevated in AR expressing LnCaP and LnCaP:C4-2 PCa 
cells as compared to normal prostate epithelial cells. 
Having confirmed the expression of these genes in PCa 
cells, we next determined the effects of ectopic over-
expression of miR137 on the mRNA and protein levels 
of KDM1A, KDM2A, KDM2A, KDM5B, KDM7A, CBP, 
SUZ12, MED1 and NCoA2. We over-expressed miR137 
and scrambled control non-targeting miRNA in PC3 cells 
which lack endogenous miR137 but which express the 
validated miR137 target KDM1A (Figure 2A). Expression 
of NCOA2 and KDM1A was reduced following miR137 
Figure 2: Identification and validation of miR137 target genes. Quantitative reverse transcriptase PCR was used to compare 
mRNA expression of putative miR137 targets in non-malignant prostate epithelial cells (PREC), androgen responsive (LNCaP) and 
(LNCaP:C4-2 and PC3) hormone refractory PCa cells. Bars = mean ±SEM. * = p < 0.05; **p < 0.005,*** = p < 0.001, **** = p < 0.0001 by 
ANOVA with Bonferroni’s post hoc test for multiple comparisons. Expression of all putative targets examined was similar or significantly 
higher in LnCaP and LnCAP:C4-2 PCa cell lines as compared to non-malignant PREC. Bars represent mean ±SEM of biological triplicate 
experiments.
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over-expression (Figure 3B, 3C). Quantitative RTPCR and 
western blot analyses indicated that expression levels of 
NCoA2, KDM2A, KDM4A, KDM5B, KDM7A and MED1 
mRNA and protein (Figure 2) were decreased following 
over-expression of miR137. Expression of CBP transcript 
levels was unaffected by miR137 (Figure 3I). Although the 
decrease in SUZ12 did not reach statistical significance 
(Figure 3J), interestingly SUZ12 protein levels were 
decreased by miR137 expression (Figure 3K). Previous 
studies have indicated NCOA2 is regulated by miR137 
in other cancer types [13, 38]. Therefore we included 
NCOA2 both as a positive control in our studies and to 
confirm that this regulation is conserved in prostate cancer. 
GAPDH was used as a loading control.
Figure 3: Quantitative RTPCR indicates ectopic over-expression of miR137 in PC3 cells induces decreases in mRNA
levels of NCoA2/SRC2, KDM1A/LDS1, KDM2A, KDM4A, KDM5B, KDM7A, and MED1 A.-H. although the expression 
of CBP and SUZ12 was not significantly reduced I.-J. Bars represent mean ±SEM of triplicate experiments conducted on at least two 
independent occasions. * = p < 0.05; **p < 0.005,*** = p < 0.001, **** = p < 0.0001 by ANOVA with Bonferroni’s post hoc test for 
multiple comparisons. Western blot analyses on extracts from PC3 cells expressing miR137 or scramble controls confirmed the reduced 
protein levels including in the case of SUZ12 (K.). Thus SUZ12 protein was decreased in PC3 cells over-expressing miR137, suggesting 
potential post-translational regulation of SUZ12 protein levels by miR137. qRTPCRs and western analyses were completed on a minimum 
of three biological replicates.
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To confirm these findings RNAhybrid [39] was used 
to calculate the minimum free energy for hybridization 
of miR137 with target UTRs where we had evidence 
indicating that miR137 decreases both mRNA and protein 
expression. We compared the calculated minimum free 
energy for known validated miR137 targets KDM1A 
(-19.4 kcal/mol) and NCoA2 (-19.9 kcal/mol). To test 
if KDM2A, KDM4A, KDM5B, KDM7A and MED1 are 
direct targets of miR137 we generated luciferase reporter 
constructs using the psiCHECK2 vector containing the 
predicted miR137 target sequences identified within the 
3’UTR of each putative novel target (Figure 4A-4E). Each 
reporter was cotransfected into PC3 cells with either the 
miR137 or miR-scrambled control expression construct. 
Over-expression of miR137 had no effect on luciferase 
reporter activity of the parental psiCHECK2 vector (data 
not shown), whereas over-expression of miR137 caused 
a significant decreases in the relative luciferase reporter 
activity for each of the psiCHECK2 constructs harboring 
the putative 3’UTR target sequences for each gene, as 
compared to cells transfected with the scrambled miR 
negative control (Figure 4). This suggests that KDM2A, 
KDM4A, KDM5B, KDM7A and MED1 are direct targets 
of miR137.
Regulation of miR137 expression in prostate 
cancer cells
We next assessed the relationship between androgen 
and miR137 expression. To this end, we used the integrated 
genome viewer [40] and the appropriate genome build 
to interrogate publically available AR genomewide 
chromatin immune-precipitation (ChIP) (GSE22076, 
GSE28219, GSE48308,GSE14092/97) datasets and 
identified AR recruitment to the miR137 locus in androgen 
responsive, non-malignant muscle cells [41] (Figure 5A). 
Consistent with this, androgen treatment of androgen 
responsive LNCaP cells induced miR137 expression 
(Figure 5B). We and others have previously shown that 
KDM1A is a crucial component of androgen induced 
and AR-mediated transcription in PCa cells [14-17, 42, 
43]. We therefore tested whether KDM1A is involved in 
androgen regulation of miR137 expression. To this end we 
used siRNA to functionally deplete KDM1A expression 
in LNCaP cells (Figure 5C) as previously described [14]. 
We found that KDM1A is required for androgen-induced 
miR137 expression (Figure 5C, 5D). 
Effect of miR137 expression on androgen target 
gene expression in prostate cancer cells
Collectively our data support a rheostat function 
for miR137 in the autoregulation of androgen signaling, 
as depicted in Figure 5E. In non-malignant androgen 
responsive cells, AR/cofactor complexes, including 
KDMs, drive hormone-dependent transcription of target 
gene networks. This response is attenuated by induction 
of miR137 expression, which reduces levels of essential 
AR coregulators. In malignant androgen responsive cells, 
the miR137 locus can be epigenetically silenced by DNA 
methylation, allowing a sustained androgen response 
to drive androgenic proliferation pathways. Consistent 
with this, alterations in expression of these coregulators 
are associated with poorer PCa outcomes (Supplemental 
Figure 2B, 2C). To further test this model of miR137 as 
a negative regulator of androgen-dependent transcription, 
we assayed the effect of a synthetic miR137 antagomiR 
on androgen-induced expression of the prostate specific 
antigen gene, PSA/KLK3. As shown in Figure 5F, 
androgen treatment of LnCaP cells stimulated a ~6 fold 
induction in PSA/KLK3 expression. However functional 
inhibition of miR137 by transfection of anti-miR137 in 
LnCaP cells resulted in a ~9 fold androgen induction of 
PSA/KLK3 expression. Moreover ectopic expression of 
Figure 4: The RNAhybrid algorithm was used to determine the predicted hybridization of miR137 (green) and the 
3’UTRs of the novel putative miR137 targets as indicated, and luciferase reporter assays used to confirm target 
specificity: A., KDM2A  B., KDM4A C., KDM5B  D., KMD7A and E., MED1. Luciferase assays were performed in PC3 cells transfected 
with either parental psiCHECK2 or psiCHECK2-3’UTR constructs for each putative miR137 target and either a scrambled control or 
miR137 expression construct. Bars represent mean ±SEM of minimum of three biological replicate experiments conducted on at least three 
independent occasions (n = 6-9). * = p < 0.05; **p < 0.005,*** = p < 0.001, **** = p < 0.0001 by t test.
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Figure 5: A. Genomewide chromatin immune-precipitation (ChIP) assays (GSE22076) determined the distribution of the AR in muscle 
cells [41] indicate recruitment of AR (indicated in green) to the miR137 locus (indicated in blue). B. Quantitative RTPCR indicates 
expression of miR137 induced by androgen in LnCaP cells. C., D. siRNA mediated functional depletion of KDM1A indicates androgen 
induced expression of miR137 requires KDM1A. There is a significant reduction in KDM1A expression in LNCaP treated with both 
siKDM1A with androgen as compared to LNCaP treated with siKDM1A and vehicle. This suggests that androgen induction of miR137 
augments siRNA mediated depletion of KDM1A. Data shown is the mean±SEM of a minimum of five biological independent experiments 
analyzed in triplicate. E. We propose a model whereby androgens, acting via the AR-coregulator complex induce expression of miR137 
which in turn acts to reduce coregulator levels and attenuate androgen transcriptional activation. The AR is known to interact with KDM1A, 
KDM2A, KDM5B, NCOA2 and MED1 whereas AR interaction with KDM7A has not been reported to date. F. Consistent with this 
model, quantitative RTPCR indicates a synthetic miR137 antagomiR significantly enhances androgen induced transcription of PSA/KLK3 
in LnCaP cells. AntiMiR experiments were conducted on a minimum of six biological replicates analyzed in technical triplicates. G. 
Conversely ectopic expression of miR137 reduces expression of the pro-angiogenic KDM1A target gene in the PC3 cell model of castrate 
resistant PCa. Data shown is the mean±SEM of a minimum of three independent experiments analyzed in triplicate. * = p < 0.05; **p < 
0.005,*** = p < 0.001, **** = p < 0.0001.
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miR137 reduces expression of the VEGFA pro-angiogenic 
factor (Figure 5G) which we have previously shown to 
be regulated by KDM1A [14]. Taken together our results 
provide strong evidence for a central role of miR137 as 
a rheostat controlling androgen response in prostate 
cells. Induction of miR137 by AR executes a negative 
feedback loop by suppressing expression of essential AR 
coregulators, in particular the KDMs, as outlined here. 
Disruption of this pathway may therefore play a key role 
in disease progression in PCa.
DISCUSSION
There is considerable interest in the potential clinical 
value of miRs in PCa [44]. However, the successful 
exploitation of miRs as clinical prognostic markers 
and their utilization as therapeutic targets will require 
comprehensive molecular characterization of the diverse 
effects of individual miRs in distinct cellular contexts. 
It was previously established that miR137 negatively 
regulates many genes implicated in cancer including the 
transcriptional coregulators KDM1A [4, 6, 45] and NCOA2 
[13, 38], aurora kinase A (AURKA) [6], estrogen-related 
receptor ERRα/NR3B1 [12] and constitutive androstane 
receptor (CAR/NF1I3)[46], the CDC42 and CDK6 cell 
cycle regulators [7, 47], the ubiquitin ligase MIB1[48], 
COX2 [5], paxillin [49], chromosome segregation like-
1 CSE1L gene [50], glioma pathogenesis-related protein 
1 (also referred to as RTVP1) [51], the EZH2 polycomb 
protein [52] and CtBP1 [53]. Interestingly, loss or reduced 
expression of miR137 has been reported in colo-rectal 
cancer [6], neuroblastoma [4], glioblastoma [51], head 
and neck [10], non-small cell lung [54, 55] and gastric 
[56] cancers. This loss or reduction in miR137 expression 
is commonly attributable to epigenetic silencing by DNA 
methylation. In this study we show that the miR137 
locus is unmethylated in non-malignant PREC, but is 
increasingly methylated in more aggressive PCa cell 
lines (Figure 1C). Consistent with this, our analysis of the 
TCGA DNA methylation datasets confirms increased DNA 
methylation of the miR137 locus in all cancers examined 
with the exception of thyroid carcinoma. Indeed increased 
methylation of miR137 was found in higher grade PCas 
(Figure 1). Furthermore there is evidence in the TCGA 
prostate dataset presented in the cBioPortal that up to 
10% of prostate tumors harbor heterozygous deletions 
encompassing the miR137 locus [57]. Restoration of 
miR137 expression inhibits proliferation and the metastatic 
potential of colo-rectal cancer [6, 7, 49] and glioblastoma 
[51] and sensitizes cancer cells to chemotherapies [46, 58]. 
Collectively these numerous studies support an important 
role for epigenetic silencing of miR137 in carcinogenesis, 
resistance to apoptosis, promotion of metastases and 
mediating multiple mechanisms of therapeutic resistance. 
It is in this context that we have identified five nuclear 
receptor transcriptional coregulators as novel targets 
of miR137. Our work expands the known repertoire of 
validated miR137 targets as we have identified an extended 
network of known and potential AR transcriptional 
coregulators as novel miR137 targets.
The AR plays essential roles in carcinogenesis and 
metastases, most notably in prostate and bladder cancers 
[59]. For this reason, androgen deprivation therapies 
(ADTs) are commonly used to treat PCa. Although ADTs 
are often initially effective, a transition to a hormone 
refractory state in which androgen-targeted therapies 
are no longer effective appears inevitable even for next 
generation ADTs such as abiraterone and enzalutamide 
[as reviewed in 60]. Indeed, it is now understood that 
androgen signaling persists following the transition to the 
hormone refractory, castrate resistant state [19, 60, 61, 
62]. Current ADTs directly target AR function by blocking 
androgen biosynthesis (gonadotrophin releasing hormone 
analogues), acting as AR selective antagonists (flutamide, 
bicalutamide, enzalutamide) or blocking intra-tumoral 
androgen biosynthesis (abiraterone). However men 
receiving ADT commonly progress within 18 months to 
a castration resistant state for which no curative therapy is 
available. Given the essential roles for androgen signaling 
in all PCa stages, there is an urgent need to identify novel 
components of the AR signaling network which may 
represent novel PCa therapeutic targets. AR coregulators 
are attractive therapeutic targets as the AR must recruit 
a large repertoire of enzymatically diverse transcriptional 
coregulators. Indeed many of these AR coregulators are 
implicated in PCa through diverse molecular mechanisms 
[63]. These include AR coregulators with intrinsic or 
recruited lysine acetyltransferase (KATs) activity such 
as the p160 (NCOA1, NCOA2, NCOA3) and p300/
CBP coactivators [28, 63-69], lysine methyltransferases 
(KMTs) such as G9A and SYMD3 [70, 71], lysine 
demethylases (KDMs) such as KDM1A/LSD1 [16, 42], 
KDM4A/JMJD2A [72, 20], JMJD2C [15], JMJD2D [72], 
KDM5B/JARID1B [30] and the MED1 component of the 
mediator complex [73]. 
MiR137 represses KDM1A [6] and NCOA2 [38]. 
Although epigenetic loss of miR137 contributes to 
increased KDM1A expression in colo-rectal [6] and oral 
[38] cancers respectively, the mechanisms resulting in 
increased KDM1A and NCOA2 in PCa cells are not well 
understood. NCOA1, NCOA2 and NCOA3 are miR137 
targets in prostate, breast and melanoma cancers and the 
miR137 locus is silenced in PCa [13]. In our study we 
have confirmed that miR137 is epigenetically silenced 
in pre-clinical PCa cell models of localized and castrate 
resistant cancer and demonstrate that increased miR137 
methylation correlates with increasing Gleason grade 
in a clinical dataset (Figure 1). Furthermore, we have 
shown that miR137 is predicted to act as a repressor of 
an extended network of transcriptional coregulators, in 
addition to KDM1A (Supplemental Table, Figure 1). We 
first confirmed expression of the putative novel miR137 
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targets (KDM2A, KDM5B, KDM7A, CBP, SUZ12, 
MED1) and the KDM1A and NCoA2 validated miR137 
targets in PCa cell lines (Figure 2). Ectopic expression 
of miR137 in PC3 cells, which lack intrinsic miR137 
expression, results in decreased mRNA and protein 
levels of KDM1A, KDM2A, KDM4A, KDM5B, KDM7A 
and MED1 but had no effect on CBP or SUZ12 mRNA 
levels (Figure 3). However protein levels of SUZ12 
were decreased, suggesting miR137 interferes with 
SUZ12 protein levels through an alternative mechanism. 
Related to this, miR137 is known to regulate the EZH2 
component of the polycomb repressive complex 2 (PRC2) 
of which SUZ12 is also an integral component [52]. It is 
possible that miR137 mediated depletion of EZH2 induces 
dissociation of PRC2 thereby contributing to decreased 
SUZ12 observed here. In addition we found that miR137 
repressed luciferase reporters containing the predicted 
miR137 target sequences from the 3’UTR of KDM2A, 
KDM4A, KDM5B, KDM7A and MED1. Collectively, 
our data supports miR137 as a negative regulator for the 
transcriptional KDM2A, KDM4A, KDM5B, KDM7A and 
MED1 in PCa cells.
NCOA2, KDM1A, KDM4A, KDM5B and 
MED1 are AR coregulators implicated in prostate and 
other cancers [16, 30, 65, 73-78]. KDM1A promotes 
PCa recurrence by enhancing androgen induced pro-
proliferative and pro-angiogenic transcription [14, 17]. 
Similarly, NCOA2, more commonly referred to as SRC2/
TIF2 is a p160 AR coactivator implicated as an oncogene 
in prostate carcinogenesis and castrate resistance [74-78]. 
KDM2A/JHDM1A/FBXL11 acts on histone mono- and 
dimethylated histone H3K36 and is implicated in lung 
cancer [79] and the epigenetic silencing of chromatin 
[80]. The tri-methyl selective KDM4A/JMJD2A 
demethylase is an AR coregulator [72] expressed in PCa 
[14] and is a determinant of mTOR inhibitor sensitivity 
in non-small cell lung cancer patients [81]. Several 
studies have confirmed that the histone H3 lysine 4 
selective demethylase, KDM5B interacts with AR, acts 
as an AR transcriptional coactivator, is increased in 
PCa and can act as an oncogene [30, 82 and references 
therein, 82-85]. KDM7A/JHDM1D/KIAA1718 is a dual-
specificity demethylase which removes repressive marks 
on histone-H3, lysine 9 and 27 (H3K9me, H3K27me) 
[86, 87]. There is evidence that related members of this 
JHDM1-family of demethylases function as nuclear 
receptor transcriptional coregulators [88] and are 
implicated in PCa [76]. Given the ability of KDM7A to 
remove histone lysine methylation marks commonly 
associated with transcriptional repression (H3K9/K27) 
it is possible that KDM7A can also promote androgen 
induced transcription. However there is also evidence that 
in certain contexts increased JHDM1D can act as a tumor 
suppressor [89]. Further work is required to delineate the 
specific functions of these KDMs in PCa cells. KDMs are 
attractive therapeutic targets and the availability of next 
generation KDM selective inhibitors [43, 90, 91] raises 
the potential for development of novel therapies which can 
circumvent resistance to existing ADTs by targeting the 
KDM activities required for the functional AR-complex.
As little is known about the regulation of miR137 in 
prostate cells, we interrogated publically available ChIP 
datasets and identified AR recruitment to the miR137 
locus in non-malignant cells (Figure 5A). Based on this 
finding we tested the potential for androgen regulation 
of miR137 and found a significant induction of miR137 
expression in the androgen responsive LnCaP which 
possess hemi-methylated miR137 loci (Figure 5B). Thus 
androgens induce a negative regulator of AR-associated 
coregulators. We next determined whether KDM1A 
participates in androgen regulation of miR137 expression. 
To address this we used established siRNA methods to 
functionally deplete KDM1A in LnCaP cells (Figure 
5C) [14]. Consistent with our previous result (Figure 
5B), expression of miR137 is increased by androgen, 
but this androgen induction of miR137 requires KDM1A 
(Figure 5D). Furthermore, there is a significant reduction 
in KDM1A expression in LNCaP treated with both 
siKDM1A with androgen as compared to LNCaP treated 
with siKDM1A and vehicle. This suggests that androgen 
induction of miR137 augments siRNA mediated depletion 
of KDM1A (Figure 5C).
Our study has identified a negative feedback 
mechanism whereby androgens can attenuate androgen 
responsivity by titrating the levels of important 
coregulators through expression of miR137 (Figure 5). 
We hypothesized that impairment or loss of androgen 
induction of miR137 due to aberrant methylation of the 
miR137 locus would relieve this brake on coregulator 
levels and would amplify androgen signaling. To test this 
we used a synthetic miR137 antagomiR to inhibit miR137. 
We found that functional interference of miR137 in LnCaP 
cells (Figure 1B) induces a 9 fold androgen induction of 
PSA/KLK3 expression, as compared to a 6-fold induction 
of PSA/KLK3 expression obtained in androgen treated 
LnCaP cells transfected with a scrambled antagomiR 
(Figure 5F). Therefore, we show that loss of miR137 
promotes androgen induced transcription. Conversely, 
the ability of a single miR to interfere with expression 
of multiple target genes emphasizes the great potential 
in therapeutic targeting of miRs. Although significant 
pharmacologic barriers remain to the deployment of 
miRs as systemic cancer therapies, we tested the effect 
of restoration of miR137 in the PC3 model of advanced 
castrate resistant PCa. We found that restoration of 
miR137 expression decreases expression of the pro-
angiogenic factor VEGFA (Figure 5G), a key mediator of 
PCa metastases and therapy resistance [59]. 
In conclusion, our data indicates that miR137 
executes an androgen driven feedback inhibition of 
multiple AR coregulators in normal prostate epithelia 
and early stage PCa. Conversely, miR137 silencing in 
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advanced disease promotes over-expression of these 
coregulators and in turn hyper-activation of AR signaling. 
The ability of miR137 to modulate AR signaling supports 
miR137 as a potential therapeutic target for preventing or 
delaying prostate carcinogenesis and progression. Future 
studies should also focus on the multiple epigenetic effects 
attributable to the loss of miR137. Our study further 
highlights the important role of reciprocal regulatory 
networks involving microRNAs, nuclear receptors and 
coregulators in PCa. Our data supports the development 
of new therapies targeting epigenetic coregulators as 
a mechanism to overcome resistance to ADTs which 
currently target the AR but not the associated coregulator 
components of the AR complex. 
MATERIALS AND METHODS
Bioinformatics: miR target prediction, clinical 
correlation, protein network analysis and statistics
A survey of putative targets of miR137 was 
conducted using PicTar [32], TargetScan [33], miRDB 
[34], and miRanda (microRNA.org) target prediction 
algorithms [35, 92]. RNAhybrid was used to determine the 
minimum free energy requried for hybridization of miR137 
and the predicted novel targets [39]. Candidates identified 
by a minimum of two prediction algorithms and with a 
known function in transcripion were selected for further 
analysis. The MethHC tool [36] was used to statistically 
compare methylation of the miR137 locus in tumor and 
non-tumor tissue from the TCGA database. The UCSC 
cancer genome browser [93] was used to correlate miR137 
locus methylation with PCa recurrence. Statistical analysis 
was performed using GraphPad Prism 5.04 (GraphPad, La 
Jolla, CA). For qPCR and luciferase reporter experiments 
t-tests, one-way ANOVA with Dunnett’s and/or Bonferroni 
post-test multiple comparison test was performed using 
GraphPad Prism. P-values < 0.05 were considered 
statistically significant with 95% confidence intervals. 
Cell culture, transfection, siRNA, androgen 
(R1881) treatments
Normal prostate epithelial cells (PREC) and PCa 
cell lines LNCaP, LNCaP:C4-2 and PC-3 cells were 
maintained as described previously [14, 94]. PREC 
were sourced from Lonza (Walkersville, MD), LnCaP 
and PC3 were purchased from ATCC. LnCaP:C4-2 
were a generous gift from Dr. Doug Scherr, Department 
of Urology, Weill Cornell Medical College. Androgen 
treatment (R1881) and siRNA depletion of KDM1A 
and luciferase as negative control were conducted as 
previously described [14, 95]. PC3 cells were stably 
transfected with over-expression constructs for human 
miR137 and scrambled controls (#HmiR0011-MR04 
and #CmiR0001-MR04, GeneCopoeia, Inc.), using 
Lipofectamine 2000 (Invitrogen). Transfection efficiency 
was 80-90% as assessed by GFP expression and stable 
transfectants selected using puromycin (4µg/ml). Total 
RNA and protein were isolated from three independent 
stably transfected PC3 lines expressing miR137 or the 
scrambled control. 
DNA methylation analysis, RNA extraction and 
Taqman real-time PCR
The methylation status of the miR137 locus 
in PREC, LNCaP, LNCaP:C4-2 and PC-3 cells was 
determined by performing methylation specific analysis on 
bisulfite modified DNA essentially as previously described 
[6]. Genomic DNA (350ng) was subject to bisulfite 
conversion using the EZ-DNA Methylation Kit (#D5001; 
Zymo Research Corporation, Orange, CA) according to 
the manufacturer’s instructions. The methylation status 
of the miR137 locus was determined using bisulfite 
sequencing PCR (BSP) or methylation specific PCR 
(MSP) [6]. BSP products were cloned into pGEM-T 
(Promega, Southampton, UK), transformed into SURE 
E.coli competent cells (Stratagene/Agilent Technologies, 
Wokingham, UK). A minimum of 10 independent colonies 
were selected and plasmids containing the BSP inserts 
were sequenced directly to assess percentage methylation 
[96]. 
RNA (miRNA and total) was extracted using 
miRNeasy Mini kit (Qiagen, Crawley, UK) according 
to manufacturer’s instructions. For miRNA quantitative 
reverse transcription polymerase chain reaction (qPCR) 
expression analysis, RNA (1µg) was reverse transcribed 
using the miScript reverse transcription kit (Qiagen, 
Crawley, UK) and miR-specific assays for human miR137 
(MS00003486) and the RNUD6 (218293) and/or snoRD6 
(MS00033705) normalization controls (Qiagen, Crawley, 
UK). For mRNA expression analysis, RNA (1µg) was 
reverse transcribed using qScript cDNA SuperMix (Quanta 
Biosciences, VWR, Lutterworth, UK) [14]. The resulting 
cDNA was used as a template for hydrolysis probe 
qPCR using the following gene specific hydrolysis probe 
assays (Invitrogen/Life Technologies/Thermo Scientific, 
Renfrew, UK): KDM1A (Hs01002741_m1), KDM2A 
(Hs00367034_m1), KDM4A (Hs00206360_m1), KDM5B 
(Hs00981910_m1), KDM7A (Hs01398501_m1), MED1 
(Hs01062349_m1), NCoA2 (Hs00896114_m1), CBP 
(Hs00231733_m1), SUZ12 (Hs00248742_m1), VEGFA 
(Hs00900055_m1) and GAPDH (Hs03929097_g1). All 
qPCR experiments were carried out on a minimum of 
three independent RNA isolations analyzed in triplicate.
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miR target validation
Luciferase reporter contructs were generated 
containing the predicted miR137 target sequences from 
3’-UTRs of each of the identified putative miR137-targets 
with a known role in transcription (KDM1A, KDM2A, 
KDM4A, KDM5B, KDM7A, MED1, and NCoA2). 
NCoA2 has previously been shown to be a direct miR137 
target and was therefore included as a positive control 
target 3’-UTR. The predicted miR137 target sequences 
identified within the 3’UTR of the putative novel targets 
were cloned into XhoI and NotI sites of the psiCHECK2 
luciferase reporter construct (Promega) using the primers 
indicated (Table 1). An empty psiCHECK2 vector 
was used as negative control. Plasmid DNA for over-
expression constructs for human miR137 and scrambled 
controls (#HmiR0011-MR04 and #CmiR0001-MR04, 
GeneCopoeia, Inc. Rockville, MD), psiCHECK2 negative 
control and psiCHECK2-3’UTR constructs for the 
identified targets were prepared using Prepease endotoxin 
free midiprep kit (USB). PC3 cells (1 x 105), which lack 
endogenous miR137 expression (Figure 1C), were plated 
in 24-well plates and allowed to attach for 24 hours prior 
to transfection. Cells were transfected with constructs 
expressing miR137 or a scrambled control and either 
the psiCHECK2 empty vector control or psiCHECK2 
containing the 3’UTR of the putative miR137 targets of 
the genes identified. A total of 500ng DNA was used per 
well and cells were transfected using lipofectamine 2000 
(Invitrogen/LifeTechnologies/ThermoScientific) according 
to the manufacturer’s instructions. After 48 hours, cells 
were harvested and luciferase activity measured using 
the dual luciferase assay system (Promega) with a Turner 
TD-20/20 luminometer (Turner Designs, Sunnyvale, CA) 
as previously described [97]. Data were normalized to 
firefly luciferase. Luciferase experiments were conducted 
in triplicate and repeated on three independent occasions. 
The miR137 antagomiR (MIN0000429) was purchased 
from Qiagen and transfected into LNCaP cells using 
lipofectamine 2000 (Invitrogen/ Life Technologies/ 
ThermoScientific) according to the manufacturer’s 
directions. Cells were grown at 37oC for 72 hours prior 
to RNA isolation and quantitative RTPCR as described 
earlier.
Western blotting 
For protein expression analysis, after three days 
in culture PC-3-miR137 and PC-3-scrambled control 
expressing cells were washed with PBS and lysed in SDS 
denaturing buffer (100 mM Tris-HCl pH 6.8, 4% SDS 
and 20% glycerol). The protein concentration in the cell 
lysates was quantified using the Bio-Rad DC Protein assay 
(Bio-Rad, Hercules, USA). Protein samples (10 µg) were 
boiled in loading buffer (83 mM Tris pH 8.8, 30% sucrose, 
0.00083% bromophenol blue, 3% SDS and 8.3mM DTT) 
for 5 minutes, separated on 10% SDS-PAGE gels, and 
transferred to polyvinylidene difluoride membranes 
(Millipore Corporation, Bedford, USA). Membranes 
were blocked in 5% non-fat-milk for 1 hour and probed 
with primary antibodies against KDM2A/JHDM1A 
(Thermo Scientific; #PA5-11177; 5 µg/ml), KDM4A/
Table 1. 
Gene Forward (5'-3') Reverse (5'-3')
KDM2A ccgctcgaggaagccctacagagttagggaatg ataagaatgcggccgcagtttctttctaaggccagttaatg
KDM4A ccgctcgagcccaggattggagggcttcacacc ataagaatgcggccgccattttattgctaaggacaaggtgatgc
KDM5B ccgctcgaggaaattccagtaaatcctcatttg ataagaatgcggccgcaatcgctaaagcaccaacacac
KDM7A ccgctcgaggtaagaacactgcccgaagaacag ataagaatgcggccgcgaaaatacatcaagacactaccaac
MED1 ccgctcgaggtgcatgtatatgaagggctggg ataagaatgcggccgcccatgactcaaacggacaactac
Table 2.
Coregulator Histone substrate Non-histone substrates
KDM1A(LSD1/AOF1) H3K4me2/1; H3K9me2/1 p53, E2F1, SNMT1
KDM2A (JHDM1A/FBXL11) H3K36me2/1 p65, NF-kB
KDM4A (JMJD2A) H3K9me3;H3K36me3, H1.4K26me3/2
KDM5B (JARID1B) H3K4me3/2
KDM7A (JHDM1D/KIAA1718) H3K9me2/1; H3K27me2/1
MED1 (DRIP205/TRAP220) histone acetylation via CBP/p300
NCOA2 (SRC2/TIF2) intrinsic histone acetylation and via CBP/p300
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JMJD2A (Cell Signaling Technology, Danvers, MA; 
#3393; 1:500), KDM5B/JARID1B (Cell Signaling; #3273; 
1:1000), KDM7A/JHDM1D (Sigma-Aldrich, Gillingham, 
UK; #SAB2101190; 1 µg/ml), MED1/TRAP220 (R&D 
Systems, Abingdon, UK; #AF5520; 1 µg/ml), SUZ12 
(Cell Signaling; #3737; 1:1000), NCoA2/TIF2 (BD 
Transduction Laboratories, Oxford, UK; #610985; 0.25 
µg/ml), and GAPDH (Abcam, Cambridge, UK; #ab9484; 
1 µg/ml) at 4 °C overnight. Secondary antibodies used 
were donkey anti-goat, goat anti-mouse and goat anti-
rabbit conjugated with horseradish peroxidase (Santa Cruz 
Biotechnology, Inc., Wembley, UK). Antibody binding 
was visualized using Amersham ECL Prime Western 
Blotting Detection Reagent (GE Healthcare, Amersham, 
UK). Western blots were performed on whole cell extracts 
from three independent transfections. 
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